BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16080799)

  • 1. Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.
    Li M; Liu X; Zhou S; Li P; Li G
    BMC Cancer; 2005 Aug; 5():96. PubMed ID: 16080799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
    Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
    Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
    Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
    Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells.
    Li MS; Ma QL; Chen Q; Liu XH; Li PF; Du GG; Li G
    World J Gastroenterol; 2005 May; 11(17):2564-9. PubMed ID: 15849812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
    Zhang J; Xu G
    Cancer Genet Cytogenet; 2007 Dec; 179(2):112-7. PubMed ID: 18036397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S; Vega M; Garban H; Bonavida B
    Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
    Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
    Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
    Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
    J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceramide-induced cell death is independent of the Fas/Fas ligand pathway and is prevented by Nur77 overexpression in A20 B cells.
    Brás A; Albar JP; Leonardo E; de Buitrago GG; Martínez-A C
    Cell Death Differ; 2000 Mar; 7(3):262-71. PubMed ID: 10745271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
    An S; Yap D; Knox KA
    Cell Immunol; 1997 Nov; 181(2):139-52. PubMed ID: 9398401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FADD deficiency sensitises Jurkat T cells to TNF-alpha-dependent necrosis during activation-induced cell death.
    Lawrence CP; Chow SC
    FEBS Lett; 2005 Nov; 579(28):6465-72. PubMed ID: 16289096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade.
    Gastman BR; Yin XM; Johnson DE; Wieckowski E; Wang GQ; Watkins SC; Rabinowich H
    Cancer Res; 2000 Dec; 60(24):6811-7. PubMed ID: 11156370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
    Sylvester PW; Shah S
    Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells.
    Naujokat C; Sezer O; Possinger K
    Biochem Biophys Res Commun; 1999 Nov; 264(3):813-9. PubMed ID: 10544014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
    Zhu Q; Liu JY; Yang CM; Xu HW; Zhang AZ; Cui Y; Wang HB; Qin CY; Li YQ
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1071-7. PubMed ID: 16957513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand.
    Li M; Zhou S; Liu X; Li P; McNutt MA; Li G
    Cancer Lett; 2007 May; 249(2):227-34. PubMed ID: 17046153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
    Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
    Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
    Imai T; Adachi S; Nishijo K; Ohgushi M; Okada M; Yasumi T; Watanabe K; Nishikomori R; Nakayama T; Yonehara S; Toguchida J; Nakahata T
    Oncogene; 2003 Dec; 22(58):9231-42. PubMed ID: 14647441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.